The USFDA has approved lazertinib in combination with amivantamab for treating adults with locally advanced or metastatic non-small cell lung cancer (NSCLC). This combination therapy is indicated as the first-line treatment specifically for NSCLC patients with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations.
Clinical evidence In a clinical trial conducted among 858 patients, lazertinib combination therapy achieved 23.7 months of progression-free survival compared to 16.6 months in patients treated with osimertinib. Administration 240 mg tablet; orally once daily with or without food, along with amivantamab Warnings Venous thromboembolic events Interstitial lung disease/pneumonitis Dermatologic and ocular adverse reactions Embryo-fetal toxicity Adverse reactions – Rash, musculoskeletal pain, nail toxicity, infusion-related reaction…
